Inhibiting tumor-cell growth by novel truncated staphylococcal enterotoxin C2 mutant

Hui Jing,Xiao Fang,Li Hui,Cui Xiaojin,Liu Hongsheng,Hu Fengqing

2011-01-01

Abstract:Clinical application of staphylococcal enterotoxin C2(SEC2)was restricted during the cure of malignant tumor due to its side-effects.The aim of this study was to obtain SEC2 mutant,preserving the important functional sites responsible for the T-cell stimulatOry activities but removing the sites responsible for emetic activity,through truncation of SEC2.It would efficiently solve the question of SEC2 side-effect.According to the results of methyl thiazol tetrazolium(MTT)assay in vitro,novel truncated SEC2 mutant(NSM)efficiently stimulated T-cell proliferation and inhibited the growth of such tumor cells as human colorectal cancer cells(Cx-1)and human breast cancer cells(MCF-7)in vitro.Activities of T cell stimulating and anti-tumor of NSM were similar to those of SEC2.According to results of animal experiments,the mutant no longer induced emetic response even if the dose was a 10-fold excess of the amount of SEe2 required.And also,NSM obviously inhibited the tumor growth in tumor-bearing mice.Therefore,we obtained novel truncated staphylococcal enterotoxin C2 mutant,which could efficiently inhibit the growth of tumor cells.It will become novel anti-tumor agents with the lowest side-effects and best treatment effects in clinic.